News

Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
StockStory.org on MSN6h
Abbott Laboratories’s (NYSE:ABT) Q2 Sales Top Estimates
Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2025, with sales up 7.4% year on year to $11.14 ...
InvestorsHub on MSN5h
Abbott’s Q2 revenue surpasses expectations despite share decline
Abbott Laboratories (NYSE:ABT) reported second-quarter earnings that modestly beat analyst forecasts, yet the company’s shares dropped 2.5% following the announcement. The healthcare leader posted ...
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine.
International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...
GazetteXtra6d
S&P 500 rises to record as Treasury sale goes well: Markets wrap
Relative calm enveloped Wall Street, with stocks rising as traders parsed a batch of corporate outlooks. Treasuries bounced from session lows as a $22 billion sale of 30-year bonds showed ...